Lifestyle and hemostatic risk factors for ischemic heart disease: The Caerphilly Study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 1, 2000, Pages 271-279

  Yarnell, John W G ^a   Sweetnam, Peter M ^b   Rumley, Ann ^c   Lowe, Gordon D O ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Epidemiological study; Heart disease; Hemostatic factors; Lifestyle

Indexed keywords

FIBRINOGEN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD VISCOSITY; BODY MASS; DISEASE ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0033977272     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.1.271     Document Type: Article

References (47)

1. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischemic heart disease in the Caerphilly study. Thromb Haemost. 1998;79:129-133.
2. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Thomas HF, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischemic heart disease in the Caerphilly Study. Br J Haematol. 1999;105:110-116.
3. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white cell count are major risk factors for ischemic heart disease. Circulation. 1991;83: 836-844.
4. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:963-965.
5. Yarnell JWG, Sweetnam PM, Rogers S, Elwood PC, Bainton D, Baker IA, Eastham R, O'Brien JR, Etherington NW. Some long term effects of smoking on the hemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol. 1987;40:909-913.
6. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ. 1979;1:153-156.
7. Elwood PC, Yarnell JWG, Pickering J, Fehily AM, O'Brien JR. Exercise, fibrinogen, and other risk factors for ischemic heart disease: Caerphilly Prospective Heart Disease Study. Br Heart J. 1993;69:183-187.
8. Sweetnam PM, Yarnell JWG, Lowe GDO, Baker IA, O'Brien JR, Rumley A, Etherington MD, Whitehead PJ, Elwood PC. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol. 1998;100:582-588.
9. Poulter N, Sever P, Thom S, eds. Cardiovascular Disease: Risk Factors and Intervention. Oxford, UK: Radcliffe; 1993.
10. Sweetnam PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischemic heart disease. Eur Heart J. 1996;17:1814-1820.
11. Bainton D, Miller NE, Bolton CH, Yarnell JWG, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischemic heart disease in British men: the Caerphilly and Speedwell collaborative heart disease studies. Br Heart J. 1992;68:60-66.
12. Rose GA Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: World Health Organization; 1982.
13. Yarnell JWG, Fehily AM, Milbank JE, Sweetnam PM, Walker CL. A short dietary questionnaire for use in an epidemiological survey: comparison with weighed dietary records. Hum Nutr Appl Nutr. 1983;37A: 103-112.
14. Shapiro S, Weinblatt E, Frank CW, Sager RV. The H.I.P. study of incidence and prognosis of coronary heart disease: preliminary findings on incidence of myocardial infarction and angina. J Chronic Dis. 1965; 18:527-558.
15. Taylor HL, Jacobs DR, Schucker B, Knudsen J, Leon AS, de Backer G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31:741-755.
16. Durrington PN, Ishola M, Hunt LP, Arrol S, Bhatnagar D. Apolipoproteins (a), A-I, and B, and parental history in men with early onset ischemic heart disease. Lancet. 1988;1:1070-1073.
17. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441-446.
18. Rumley A, Lowe GDO, Lee AJ, Tunstall-Pedoe HD. Effect of age, sex and menopause on fibrinolytic variables. Fibrinolysis. 1992;6(suppl 3):73. Abstract.
19. Lee AJ, Fowkes GR, Lowe GDO, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1995;15:1094-1097.
20. Eliasson M, Evrin P-E, Lundblad D, Asplund K, Ranby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis. 1993;7:316-323.
21. Conlan NG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1998;79:129-133.
22. Lowe GDO, Smith WCS, Tunstall-Pedoe HD, Crombie IK, Lennie SE, Anderson J, Barbenel JC. Cardiovascular risk and haemorheology: results from the Scottish Heart Health Study and the MONICA Project, Glasgow. Clin Hemorheol. 1988;8:518-524.
23. Eliasson M, Asplund K, Evrin P-E, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: the Northern Sweden MONICA Study. Atherosclerosis. 1995;113:41-53.
24. Allen RA, Kluft C, Bronmer EJP. Effect of chronic smoking on fibrinolysis. Arteriosclerosis. 1985;85:443-450.
25. Yamell JWG. The role of hemostatic factors in cardiovascular disease: a review. Primary Cardiol. 1992;18:68-74.
26. Meade TW, Imeson J, Stirling Y. Effect of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet. 1987;2:986-988.
27. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham study. Am Heart J. 1987;113:1006-1010.
28. Royal College of Physicians. Smoking or Health? London, UK: Pitman; 1983.
29. Beaglehole R, Jackson R. Alcohol, cardiovascular diseases and all causes of death: a review of the epidemiological evidence. Drug Alcohol Rev. 1992;11:275-290.
30. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease. JAMA. 1998;279:1477-1482.
31. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue type plasminogen activator. JAMA. 1994;272: 929-933.
32. Lee AJ, Flanagan PA, Rumley A, Fowkes FGR, Lowe GDO. Relationship between alcohol intake and tissue-plasminogen activator antigen and other hemostatic factors in the general population. Fibrinolysis. 1995;9: 49-54.
33. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
34. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Tliromb Vasc Biol. 1997;17: 3321-3325.
35. Nilsson TK, Jansson JH, Boman K. t-PA-PAI-1 complex as a risk factor for the development of a first stroke. Fibrinolysis. 1998;12(suppl 1):21. Abstract.
36. Hendriks HF, Veenstra J, Velthuis-te Wierik EJ, Schaafsma G, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. BMJ. 1994;308:1003-1006.
37. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652-659.
38. Jousilhti P, Tuomilehto J, Vartianen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors and coronary mortality. Circulation. 1996;93:1372-1379.
39. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Nonsjö, Sweden. J Clin Epidemiol. 1989;42:719-23.
40. Eliasson M, Evrin P-E, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure: the Northern Sweden MONICA Study. J Clin Epidemiol. 1994;46:513-524.
41. Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis. 1996;10:127-136.
42. Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J. 1995;16:47-53.
43. Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen and factor VII activity. Br Heart J. 1992;67:351-354.
44. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol. 1990;43:913-919.
45. Lowe GDO, Small M. Stimulation of endogenous fibrinolysis. In: Kluft C, ed. Tissue-Type Plasminogen Activator t-PA: Physiological and Clinical Aspects, Volume II. Boca Raton, Fla: CRC Press; 1988:129-171.
46. Scanu AM, Scandiani L. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med. 1991;36:249-270.
47. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.